Blood Cancer Talks

In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies.  Here are the key studies that we touched upon:

1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL:
2. Meta-analysis of >2500 patients with chromosome 1q21 abnormalities:
3. Predicting ultra-high risk myeloma by molecular profiling (including SKY92 GEP signature):
4. French data on adverse prognostic impact of del(1p32):
5. S1211 study: The first high-risk enrichment RCT in myeloma (VRD vs Elo-VRD):
6. Outcome of “double-hit” patients in MASTER and Dara-VRD arm of GRIFFIN trial:
7. Impact of Auto-Transplant on decreasing MRD burden in high-risk myeloma (including double-hits):

8. Preliminary results from GMMG-CONCEPT trial in high-risk myeloma:

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk